Polymeric Nanocarrier-Based Drug Formulations for Enhancing Nose-to-Brain Delivery. 2025

Tobeka Naki, and Sijongesonke Peter, and Sibusiso Alven
Department of Chemistry, University of Fort Hare, Alice Campus, Alice 5700, Eastern Cape, South Africa.

Neurological-related diseases are among the most debilitating and difficult to manage. Many possible pharmacological treatments for neurological diseases struggle to cross the blood-brain barrier (BBB) to achieve concentrations that can produce a therapeutic benefit. This is primarily because of the existence of the BBB, which poses significant hurdles for both therapeutic and diagnostic efforts by restricting the entry of most medications. Nasal-to-brain drug transportation has surfaced as an encouraging approach to tackle the difficulties linked with conventional drug administration techniques for neurological disorders. In response, innovative methods for improving drug delivery focus on breaking down the BBB via physical techniques, including optical and photothermal therapy, electrical stimulation, and acoustic or mechanical stimulation. Nanocarriers represent a promising approach for facilitating nasal systemic and brain delivery of active compounds. Hence, the achievement of therapeutically relevant concentrations of exogenous molecules within the body is significantly contingent upon the nanocarriers' capability to surpass biological barriers. Polymers in nanocarrier formulations can result in significantly enhanced nose-to-brain drug delivery by protecting drugs from premature biodegradation, increasing permeability, improving mucoadhesion, and targeting specific cells in the brain. Polymeric nanocarriers are frequently functionalized with cell-penetrating peptides to further improve the specificity of the loaded therapeutic molecules. This review focuses on the use of nanocarrier-based therapeutic agents to enhance the efficacy of nose-to-brain delivery systems.

UI MeSH Term Description Entries

Related Publications

Tobeka Naki, and Sijongesonke Peter, and Sibusiso Alven
April 2025, Pharmaceuticals (Basel, Switzerland),
Tobeka Naki, and Sijongesonke Peter, and Sibusiso Alven
August 2020, Drug delivery and translational research,
Tobeka Naki, and Sijongesonke Peter, and Sibusiso Alven
July 2025, Nanoscale,
Tobeka Naki, and Sijongesonke Peter, and Sibusiso Alven
August 2019, Journal of pharmaceutical sciences,
Tobeka Naki, and Sijongesonke Peter, and Sibusiso Alven
January 2023, Current neuropharmacology,
Tobeka Naki, and Sijongesonke Peter, and Sibusiso Alven
May 2023, Acta pharmaceutica Sinica. B,
Tobeka Naki, and Sijongesonke Peter, and Sibusiso Alven
June 2025, Expert opinion on drug delivery,
Tobeka Naki, and Sijongesonke Peter, and Sibusiso Alven
February 2019, Pharmaceutics,
Tobeka Naki, and Sijongesonke Peter, and Sibusiso Alven
August 2025, Journal of materials chemistry. B,
Tobeka Naki, and Sijongesonke Peter, and Sibusiso Alven
June 2012, Therapeutic delivery,
Copied contents to your clipboard!